Hemispherx Biopharma, Inc. (NYSE: HEB) Jumps 26% After Detailing of Significant Progress in Ampligen Ovarian Cancer Program
Hemispherx Biopharma, Inc. (NYSE: HEB) is engaged as an immune-pharma company that is focused on the research, development, and commercialization ...
